Effect of Once-weekly Subcutaneous Administration of NNC0487-0111 on Energy Intake, Appetite and Postprandial Metabolism in Participants With Obesity - a Randomised, Placebo-controlled, Double Blinded Study
Latest Information Update: 07 Apr 2026
At a glance
- Drugs Zenagamtide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms NN9490-8151
- Sponsors Novo Nordisk
Most Recent Events
- 27 Mar 2026 New trial record